This work was previously presented as an abstract at the 21st Annual Meeting of the American College of Veterinary Internal Medicine, Charlotte, NC, June 2003.
Effect of Pimobendan on Case Fatality Rate in Doberman Pinschers with Congestive Heart Failure Caused by Dilated Cardiomyopathy
Article first published online: 4 JUN 2008
Copyright © 2008 by the American College of Veterinary Internal Medicine
Journal of Veterinary Internal Medicine
Volume 22, Issue 4, pages 897–904, July–August 2008
How to Cite
O'Grady, M.R., Minors, S.L., O'Sullivan, M.L. and Horne, R. (2008), Effect of Pimobendan on Case Fatality Rate in Doberman Pinschers with Congestive Heart Failure Caused by Dilated Cardiomyopathy. Journal of Veterinary Internal Medicine, 22: 897–904. doi: 10.1111/j.1939-1676.2008.0116.x
- Issue published online: 4 JUL 2008
- Article first published online: 4 JUN 2008
- Submitted May 15, 2007; Revised August 11, 2007; Accepted February 13, 2008.
- Congestive heart failure;
- Dilated cardiomyopathy;
- Doberman Pinscher;
Background: Despite traditional therapy of a diuretic, angiotensin converting enzyme inhibitor, digoxin, or a combination of these drugs, survival of dogs with dilated cardiomyopathy (DCM) is low. Pimobendan, an inodilator, has both inotropic and balanced peripheral vasodilatory properties.
Hypothesis: Pimobendan when added to conventional therapy will improve morbidity and reduce case fatality rate in Doberman Pinschers with congestive heart failure (CHF) caused by DCM.
Animals: Sixteen Doberman Pinschers in CHF caused by DCM.
Methods: A prospective randomized, double-blind, placebo-controlled study with treatment failure as the primary and quality of life (QoL) indices as secondary outcome variables. Therapy consisted of furosemide (per os [PO] as required) and benazepril hydrochloride (0.5 mg/kg PO q12h) and dogs were randomized in pairs and by sex to receive pimobendan (0.25 mg/kg PO q12h) or placebo (1 tablet PO q12h).
Results: Pimobendan-treated dogs had a significant improvement in time to treatment failure (pimobendan median, 130.5 days; placebo median, 14 days; P= .002; risk ratio = 0.35, P= .003, lower 5% confidence limit = 0.13, upper 95% confidence limit = 0.71). Number and rate of dogs reaching treatment failure in the placebo group precluded the analysis of QoL.
Conclusions and Clinical Importance: Pimobendan should be used as a first-line therapeutic in Doberman Pinschers for the treatment of CHF caused by DCM.